The New Orleans firm launched two products last week for DNA quantification and typing of forensics samples.
An investigation and follow-up analysis concluded that the Trioplex test promoted by the CDC was equally sensitive to an alternative singleplex Zika assay, despite the microbiologist's claims to the contrary.
The firm's technology, called genotyping by random amplicon sequencing, or GRAS, should improve the efficiency of identifying and selecting markers for crop improvement.
The funding supports development of biochemistry and microfluidics for digital droplet multiple displacement amplification.
The deal is the latest in a series of such arrangements Mobidiag has inked for its Amplidiag diagnostic product line in recent months.
In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.
A BMJ study says that about half of former hematology-oncology regulators now work for industry.
Science should wish PhDs who leave academia well, a Nature editorial says.
New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.